Skip to main content
Complete Olympic Games coverage at your fingertips
Your inside track on the Olympic Games
Enjoy unlimited digital access
$1.99
per week for 24 weeks
Complete Olympic Games coverage at your fingertips
Your inside track onthe Olympics Games
$1.99
per week
for 24 weeks
// //

Bellus Health Inc TSX: BLU-T

Today's Change
Volume
Real-Time Last Update TSX Last Sale

Today's Trading

Day Low 3.52
Day High 3.75
Open:3.56
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

More stories below advertisement

Description
BELLUS Health Inc is a clinical-stage biopharmaceutical development company advancing novel therapeutics for conditions with a high unmet medical need, including BLU-5937, P2X3 antagonist that has the potential to be a best-in-class therapeutic for chronic cough. The company operates in one business segment namely, the development of drug candidates for health solutions.

Fundamentals

Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Earnings

Corporate earnings are provided from Morningstar, including Income Statements,Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research.

Strong Buy

StockReports+

A premium report that provides detailed quantitative assessments of earnings, fundamentals, relative valuation, risk, price momentum and more. For subscribers only.

StockCalc

What is this stock worth in intrinsic value? View this premium StockCalc report to see this stock's valuation and how it was calculated using fundamental analysis. For subscribers only.

ValuEngine

A stock valuation and forecasting report include rating, fair value assessment, return forecasts, market ratio-based valuations and comparable analysis. Available for free with registration.

Latest Press Releases

BELLUS Health to Participate in the Jefferies Virtual Healthcare Conference
- Business Wire - Tue May 25, 6:00AM CDT
Business Wire - CMTX
Tue May 25, 6:00AM CDT
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC") and other hypersensitization-related disorders, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will be participating in a fireside chat at the Jefferies Virtual Healthcare Conference.
Morganti & Co., P.L.C. Announces the Filing of a Securities Class Action on Behalf of Investors Who Acquired Bellus Health, Inc.
- BusinessWire - Sat May 15, 11:44AM CDT
BusinessWire - CMTX
Sat May 15, 11:44AM CDT
Morganti & Co., A pro-investor law firm with licensed and experienced lawyers in Canada and the United States that represent investors announces the filing of a securities class action on behalf of investors who purchased or otherwise acquired common stock of Bellus Health, Inc. ("Bellus" or "Company") (NASDAQ: BLU, TSX: BLU, FWB: BHN0) from September 5, 2019 through July 5, 2020, inclusive (the "Class Period").
BELLUS Health to Participate in the 2021 RBC Capital Markets Global Healthcare Conference
- BusinessWire - Wed May 12, 6:00AM CDT
BusinessWire - CMTX
Wed May 12, 6:00AM CDT
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) ("BELLUS Health" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of refractory chronic cough ("RCC") and other hypersensitization-related disorders, today announced that Roberto Bellini, BELLUS Health's President and Chief Executive Officer, will be participating in a fireside chat at the 2021 RBC Capital Markets Global Healthcare Conference.
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 3.32 +9.94% increase
on 07/27/21
Period Open:3.93
Price movement based on the high, low and last over the given period.
4.00 -8.75% decrease
on 07/06/21
-0.28 (-7.12%) decrease
since 06/29/21
3-Month 3.32 +9.94% increase
on 07/27/21
Period Open:4.99
Price movement based on the high, low and last over the given period.
5.11 -28.57% decrease
on 05/03/21
-1.34 (-26.85%) decrease
since 04/29/21
52-Week 2.70 +35.19% increase
on 09/24/20
Period Open:3.28
Price movement based on the high, low and last over the given period.
6.22 -41.32% decrease
on 02/18/21
+0.37 (+11.28%) increase
since 07/29/20

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2021.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

© 2021 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies